Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18606093 | COLORECTAL CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | March 2024 | February 2026 | Allow | 23 | 0 | 0 | No | No |
| 18604659 | PROSTATE CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | March 2024 | July 2025 | Allow | 16 | 0 | 0 | No | No |
| 18416797 | ANALYTE SEQUENCING WITH NANOPORES | January 2024 | August 2025 | Allow | 19 | 2 | 1 | No | No |
| 18577460 | DEVICES, KITS, AND METHODS FOR DETERMINING INCREASED SUSCEPTIBILITY TO AND TREATMENT AND PREVENTION OF PERIODONTITIS, ALZHEIMER’S DISEASE, AND OTHER CONDITIONS | January 2024 | November 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18405371 | LUNG CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | January 2024 | April 2025 | Allow | 16 | 0 | 0 | No | No |
| 18538488 | NON-INVASIVE DETECTION OF FETAL GENETIC TRAITS | December 2023 | April 2025 | Abandon | 16 | 2 | 0 | No | No |
| 18514603 | BREAST CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | November 2023 | April 2025 | Allow | 17 | 0 | 0 | No | No |
| 18509767 | STOMACH CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | November 2023 | March 2025 | Allow | 16 | 0 | 0 | No | No |
| 18502378 | BIOMARKER FOR PREDICTING AGE IN DAYS OF PIGS, AND PREDICTION METHOD | November 2023 | April 2025 | Abandon | 18 | 2 | 1 | No | No |
| 18491272 | LIVER CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | October 2023 | August 2024 | Allow | 10 | 0 | 0 | Yes | No |
| 18473061 | DNA Damage Repair Inhibitors for Treatment of Cancer | September 2023 | March 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18455537 | METHODS OF MONITORING IMMUNOSUPPRESSIVE THERAPIES IN A TRANSPLANT RECIPIENT | August 2023 | September 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18455517 | METHODS OF MONITORING IMMUNOSUPPRESSIVE THERAPIES IN A TRANSPLANT RECIPIENT | August 2023 | September 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18455499 | METHODS OF MONITORING IMMUNOSUPPRESSIVE THERAPIES IN A TRANSPLANT RECIPIENT | August 2023 | September 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18455488 | METHODS OF MONITORING IMMUNOSUPPRESSIVE THERAPIES IN A TRANSPLANT RECIPIENT | August 2023 | May 2025 | Abandon | 20 | 2 | 1 | No | No |
| 18455480 | METHODS OF MONITORING IMMUNOSUPPRESSIVE THERAPIES IN A TRANSPLANT RECIPIENT | August 2023 | September 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18455462 | METHODS OF MONITORING IMMUNOSUPPRESSIVE THERAPIES IN A TRANSPLANT RECIPIENT | August 2023 | September 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18455527 | METHODS OF MONITORING IMMUNOSUPPRESSIVE THERAPIES IN A TRANSPLANT RECIPIENT | August 2023 | June 2025 | Abandon | 22 | 3 | 1 | No | No |
| 18455456 | METHODS OF MONITORING IMMUNOSUPPRESSIVE THERAPIES IN A TRANSPLANT RECIPIENT | August 2023 | June 2025 | Abandon | 22 | 3 | 1 | No | No |
| 18361440 | BILIARY TRACT CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | July 2023 | July 2024 | Allow | 12 | 0 | 0 | No | No |
| 18215608 | SMALL RNA PREDICTORS FOR HUNTINGTON'S DISEASE | June 2023 | February 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18170241 | ASSOCIATION OF GENETIC VARIATIONS TO DIAGNOSE AND TREAT ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) | February 2023 | July 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18167807 | DIAGNOSTIC ASSAY FOR TISSUE TRANSPLANTATION STATUS | February 2023 | March 2026 | Allow | 37 | 2 | 1 | Yes | No |
| 18160918 | SYSTEMS AND METHODS FOR DETECTING MULTI-MOLECULE BIOMARKERS | January 2023 | September 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 18091186 | CIRCULATING RNA SIGNATURES SPECIFIC TO PREECLAMPSIA | December 2022 | August 2024 | Allow | 20 | 2 | 1 | Yes | No |
| 17977723 | METHYLATED MARKERS FOR COLORECTAL CANCER | October 2022 | July 2025 | Allow | 32 | 3 | 1 | No | No |
| 17945243 | COLORECTAL CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | September 2022 | October 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17930488 | BIOMARKERS FOR THE DIAGNOSIS AND TREATMENT OF FIBROTIC LUNG DISEASE | September 2022 | July 2025 | Allow | 34 | 2 | 1 | No | No |
| 17905899 | METHODS OF DETERMINING WHETHER A SUBJECT HAS OR IS AT RISK OF HAVING A CENTRAL SEROUS CHORIORETINOPATHY | September 2022 | November 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17905511 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANSMITTER TRANSPORTERS | September 2022 | February 2026 | Allow | 42 | 2 | 1 | Yes | No |
| 17908618 | microRNAS MARKERS OF THROMBOSIS CONDITIONS | September 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17798427 | METHOD FOR EVALUATING AND PREDICTING PLACENTA-DERIVED DISEASES AND KIT | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17797253 | METHODS AND SYSTEMS FOR MULTIPLEX ALLELE DETECTION | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17816210 | METHODS AND KITS COMPRISING GENE SIGNATURES FOR STRATIFYING BREAST CANCER PATIENTS | July 2022 | July 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17796603 | DETERMINATION OF FETAL GENOTYPE USING MATERNAL BIOLOGICAL SAMPLE | July 2022 | January 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17759833 | METHOD FOR SELECTING SPERMATOZOA, IN PARTICULAR FOR MEDICALLY ASSISTED PROCREATION (MAP) | July 2022 | November 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17807774 | CHIMERIC TRANSCRIPTION FACTOR VARIANTS WITH AUGMENTED SENSITIVITY TO DRUG LIGAND INDUCTION OF TRANSGENE EXPRESSION IN MAMMALIAN CELLS | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17787035 | Genome-Wide Detection of DNA Repeats Expanded in Disease | June 2022 | December 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17778729 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17777467 | METHODS AND BIOMARKERS FOR DIAGNOSTICS, DISEASE MONITORING, PERSONALIZED DRUG DISCOVERY AND TARGETED THERAPY OF MALIGNANT AND NEURODEGENERATIVE DISEASE CONDITIONS | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17777497 | METHODS AND BIOMARKERS FOR DIAGNOSTICS, DISEASE MONITORING, PERSONALIZED DRUG DISCOVERY AND TARGETED THERAPY OF AUTOIMMUNE DISEASE CONDITIONS | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17726809 | Processes and Compositions for Methylation-Based Enrichment of Fetal Nucleic Acid From a Maternal Sample Useful for Non-Invasive Prenatal Diagnoses | April 2022 | February 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17768181 | A MACHINE LEARNING ALGORITHM FOR PREDICTING CLINICAL OUTCOMES AND IDENTIFYING DRUG TARGETS IN ISCHEMIC STROKE | April 2022 | August 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17672343 | AMPLIFICATION OF NUCLEIC ACIDS | February 2022 | November 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17669081 | METHODS FOR PROFILING AND QUANTITATING CELL-FREE RNA | February 2022 | March 2025 | Allow | 37 | 3 | 1 | Yes | Yes |
| 17579041 | Genomics-Assisted Prediction Method for Apple Fruit Quality Traits and Disease Resistance and Use Thereof | January 2022 | December 2025 | Abandon | 47 | 3 | 1 | No | No |
| 17544354 | METHODS USING CHARACTERISTICS OF URINARY AND OTHER DNA | December 2021 | December 2025 | Allow | 48 | 3 | 1 | Yes | No |
| 17497270 | Biomarkers of Cancer | October 2021 | December 2025 | Abandon | 50 | 3 | 2 | No | No |
| 17475584 | COMPOSITIONS FOR DETECTING EPIGENETIC MODIFICATIONS | September 2021 | September 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17329847 | THROMBOEMBOLIC DISEASE | May 2021 | December 2025 | Abandon | 54 | 4 | 1 | No | No |
| 17317240 | NON-INVASIVE DETECTION OF FETAL GENETIC TRAITS | May 2021 | January 2025 | Abandon | 44 | 3 | 1 | Yes | No |
| 17307152 | METHODS FOR DETECTING MUTATIONAL SIGNATURES USING TARGETED PANELS | May 2021 | November 2025 | Abandon | 54 | 4 | 1 | No | No |
| 17227157 | Biomarkers for the Identification of Prostate Cancer and Methods of Use | April 2021 | July 2025 | Abandon | 52 | 3 | 1 | No | No |
| 17222810 | DETERMINING RISK OF PROSTATE TUMOR AGGRESSIVENESS | April 2021 | February 2026 | Abandon | 59 | 3 | 1 | No | Yes |
| 17276043 | SYSTEMS AND METHODS FOR DETECTION OF DELIRIUM RISK USING EPIGENETIC MARKERS | March 2021 | September 2025 | Abandon | 55 | 1 | 2 | No | No |
| 17198897 | DETECTION OF EXPRESSION OF MARKERS USEFUL FOR PREDICTING RISK OF CATASTROPHIC INJURIES IN ATHLETIC ANIMALS | March 2021 | August 2024 | Allow | 41 | 4 | 1 | Yes | No |
| 17265102 | ELIMINATION PROBE-BASED METHOD FOR DETECTING NUMERICAL CHROMOSOMAL ABNORMALITIES, AND NUCLEIC ACID COMPOSITION FOR DETECTING NUMERICAL CHROMOSOMAL ABNORMALITIES | February 2021 | January 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17263757 | Methods of Detecting Inherited Myopathies in Horses | January 2021 | March 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17122946 | Particles with RNA Cleaving Nucleobase Polymers and Uses for Managing Inflammatory Disorders | December 2020 | October 2025 | Abandon | 58 | 2 | 1 | No | No |
| 17079196 | METHODS FOR DETECTION OF MACRO-HETEROPLASMY AND MICRO-HETEROPLASMY IN MITOCHONDRIAL DNA | October 2020 | June 2024 | Allow | 44 | 2 | 1 | Yes | Yes |
| 17028377 | Computational Design of Self-Assembling Cyclic Protein Homo-oligomers | September 2020 | September 2024 | Allow | 47 | 1 | 1 | No | No |
| 16979615 | METHODS OF IDENTIFYING, SELECTING, AND PRODUCING DISEASE RESISTANT CROPS | September 2020 | July 2024 | Allow | 46 | 2 | 1 | No | No |
| 17001144 | METHOD OF DETECTING CANCER THROUGH GENERALIZED LOSS OF STABILITY OF EPIGENETIC DOMAINS AND COMPOSITIONS THEREOF | August 2020 | July 2025 | Allow | 59 | 4 | 2 | No | No |
| 16969923 | CLASSIFIER FOR IDENTIFICATION OF ROBUST SEPSIS SUBTYPES | August 2020 | November 2025 | Allow | 60 | 2 | 1 | Yes | Yes |
| 16969304 | METHODS FOR SUBTYPING OF BLADDER CANCER | August 2020 | September 2024 | Allow | 49 | 1 | 1 | Yes | No |
| 16959431 | REFERENCE MATERIAL FOR NON-INVASIVE PRENATAL TESTING AND MANUFACTURING METHOD THEREOF | June 2020 | September 2022 | Abandon | 26 | 1 | 1 | No | No |
| 16956204 | PREDICTING CHRONIC ALLOGRAFT INJURY THROUGH ISCHEMIA-INDUCED DNA METHYLATION | June 2020 | November 2024 | Abandon | 60 | 4 | 1 | Yes | No |
| 16900275 | GENETICALLY ENCODED FLUORESCENT-IRON FERRITIN NANOPARTICLE PROBES FOR DETECTING AN INTRACELLULAR TARGET BY FLUORESCENT AND ELECTRON MICROSCOPY | June 2020 | February 2026 | Allow | 60 | 2 | 1 | Yes | No |
| 16771733 | INFECTION-RELATED PRETERM BIRTH DIAGNOSTIC METHOD | June 2020 | April 2025 | Abandon | 58 | 4 | 1 | No | No |
| 16757505 | SINGLE NUCLEOTIDE POLYMORPHISMS AND FEEDING EFFICIENCY IN CATTLE | April 2020 | September 2024 | Allow | 53 | 3 | 1 | Yes | No |
| 16838653 | GENE CLASSIFIERS FOR USE IN MONITORING UV DAMAGE | April 2020 | March 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16836498 | METHODS FOR PROFILING AND QUANTITATING CELL-FREE RNA | March 2020 | October 2025 | Allow | 60 | 3 | 2 | Yes | No |
| 16708543 | PREDICTION METHOD FOR RISK OF ISCHEMIC STROKE ONSET | December 2019 | November 2024 | Abandon | 59 | 4 | 1 | Yes | No |
| 16698411 | GENES AND POLYMORPHISMS ASSOCIATED WITH AGE RELATED MACULAR DEGENERATION (AMD) | November 2019 | January 2025 | Abandon | 60 | 1 | 1 | No | No |
| 16692276 | EVALUATING GENETIC DISORDERS | November 2019 | October 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16358825 | THERAPEUTIC TREATMENT OF SELECT DIFFUSE LARGE B CELL LYMPHOMAS EXHIBITING DISTINCT PATHOGENIC MECHANISMS AND OUTCOMES | March 2019 | November 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 15999597 | EPIGENOMIC PROFILING REVEALS THE SOMATIC PROMOTER LANDSCAPE OF PRIMARY GASTRIC ADENOCARCINOMA | August 2018 | April 2025 | Allow | 60 | 5 | 0 | Yes | No |
| 15501761 | METHOD FOR DETERMINING STATE OF DIFFERENTIATION OF STEM CELLS, AND NOVEL DIFFERENTIATION MARKER USED THEREFOR | February 2017 | May 2020 | Allow | 39 | 3 | 1 | No | No |
| 15368073 | Genomic Regions with Epigenetic Variation That Contribute to Phenotypic Differences in Livestock | December 2016 | February 2020 | Allow | 39 | 3 | 1 | Yes | No |
| 14822873 | METHOD OF USING FOXO3A POLYMORPHISMS AND HAPLOTYPES TO PREDICT AND PROMOTE HEALTHY AGING AND LONGEVITY | August 2015 | January 2020 | Allow | 53 | 5 | 1 | Yes | No |
| 14796590 | MEANS AND METHODS FOR HAPLOTYPING MHC-DRB LOCI IN MAMMALS AND USES THEREOF | July 2015 | October 2017 | Allow | 27 | 2 | 1 | Yes | No |
| 14600419 | Composition for Diagnosing Recurring Glioblastoma Multiforme and Method for Diagnosing Same | January 2015 | December 2018 | Allow | 46 | 4 | 2 | Yes | No |
| 14584788 | DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER | December 2014 | January 2018 | Allow | 36 | 3 | 1 | Yes | No |
| 14253592 | MARKERS OF TUMOR CELL RESPONSE TO ANTI-CANCER THERAPY | April 2014 | March 2018 | Allow | 47 | 3 | 1 | Yes | No |
| 13790309 | COMPOSITIONS AND METHODS FOR DIAGNOSING AUTISM | March 2013 | April 2017 | Allow | 50 | 4 | 1 | Yes | No |
| 13565105 | Haplotype Analysis | August 2012 | April 2013 | Allow | 9 | 1 | 0 | No | No |
| 13357416 | SCHIZOPHRENIA-RELATED ISOFORM OF KCNH2 AND DEVELOPMENT OF ANTIPSYCHOTIC DRUGS | January 2012 | June 2014 | Allow | 29 | 2 | 1 | No | No |
| 13255871 | GENOTYPING TOOL FOR IMPROVING THE PROGNOSTIC AND CLINICAL MANAGEMENT OF MS PATIENTS | November 2011 | May 2014 | Allow | 33 | 2 | 1 | Yes | Yes |
| 13279947 | DETECTION OF HIGH GRADE DYSPLASIA IN CERVICAL CELLS | October 2011 | March 2019 | Allow | 60 | 10 | 1 | Yes | No |
| 13203810 | METHOD FOR DETERMINING SENSITIVITY TO IRINOTECAN AND USE THEREOF | August 2011 | May 2015 | Allow | 44 | 3 | 1 | Yes | No |
| 13211373 | METHODS FOR DETERMINING THE PRESENCE OR ABSENCE OF ELITE EVENT RF-BN1 IN BRASSICA PLANT MATERIAL | August 2011 | July 2012 | Allow | 11 | 1 | 1 | No | No |
| 13155555 | METHOD FOR DIAGNOSING AUTISM SPECTRUM DISORDER | June 2011 | June 2018 | Allow | 60 | 8 | 1 | Yes | No |
| 13155199 | RGS2 GENOTYPES ASSOCIATED WITH EXTRAPYRAMIDAL SYMPTOMS INDUCED BY ANTIPSYCHOTIC MEDICATION | June 2011 | December 2014 | Allow | 42 | 4 | 1 | Yes | No |
| 13094729 | CANCER BIOMARKERS AND METHODS OF USE THEREOF | April 2011 | June 2024 | Allow | 60 | 16 | 1 | Yes | No |
| 13026173 | MARKERS FOR DETERMINATION OF PATIENT RESPONSIVENESS | February 2011 | April 2014 | Allow | 39 | 2 | 1 | Yes | Yes |
| 13019906 | DIAGNOSTIC METHODS INVOLVING DETERMINING GENE COPY NUMBERS AND SNPS IN THE FC-GAMMA-RII/ FC-GAMMA-RIII GENE CLUSTER, AND PROBES FOR USE IN SUCH METHODS TO DETECT SUSCEPTIBILITY TO AND TREATMENT EFFICACY IN AUTOIMMUNE DISEASES | February 2011 | February 2014 | Allow | 37 | 4 | 1 | Yes | Yes |
| 12981529 | METHODS AND COMPOSITIONS FOR GENETICALLY DETECTING IMPROVED MILK PRODUCTION TRAITS IN CATTLE | December 2010 | February 2016 | Allow | 60 | 2 | 1 | Yes | Yes |
| 12935098 | PROCESS AND METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE | December 2010 | March 2013 | Allow | 29 | 2 | 1 | Yes | No |
| 12969744 | NOVEL POLYMORPHISM IN BOVINE PRION PROTEIN GENE SEQUENCE | December 2010 | September 2013 | Allow | 33 | 2 | 1 | No | No |
| 12948722 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD | November 2010 | January 2012 | Allow | 14 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KAPUSHOC, STEPHEN THOMAS.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 54.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner KAPUSHOC, STEPHEN THOMAS works in Art Unit 1683 and has examined 107 patent applications in our dataset. With an allowance rate of 85.0%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 48 months.
Examiner KAPUSHOC, STEPHEN THOMAS's allowance rate of 85.0% places them in the 61% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by KAPUSHOC, STEPHEN THOMAS receive 2.86 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KAPUSHOC, STEPHEN THOMAS is 48 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +28.9% benefit to allowance rate for applications examined by KAPUSHOC, STEPHEN THOMAS. This interview benefit is in the 77% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.8% of applications are subsequently allowed. This success rate is in the 41% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 43.9% of cases where such amendments are filed. This entry rate is in the 67% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 90.9% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 60.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 70.6% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 19.6% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.2% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.